Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AKESQ SEC Suspension for delinquent Financials / filings:
http://www.sec.gov/litigation/suspensions/2015/34-74330.pdf
Order:
http://www.sec.gov/litigation/suspensions/2015/34-74330-o.pdf
Admin Proceeding:
http://www.sec.gov/litigation/admin/2015/34-74331.pdf
this could easily run to $1 imo
SEC 10Q FILED 8/7/08:
http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=6085572
RECENT NEWS:
Akesis Pharmaceuticals Enters into Bridge Financing Transaction
SAN DIEGO, Sep 30, 2008 (BUSINESS WIRE) -- Akesis Pharmaceuticals, Inc. (OTCBB: AKES), an emerging diabetes drug-development company, today announced that, on September 29, 2008, it entered into a Note and Warrant Purchase Agreement with Avalon Ventures VII, L.P. Pursuant to the Note and Warrant Purchase Agreement, the Company has the ability to sell to Avalon Ventures one or more convertible promissory notes maturing February 1, 2009 in an aggregate principal amount of up to $2.0 million. Each note will automatically convert into shares of the Company's preferred stock in the event of the closing, prior to February 1, 2009, of a preferred stock financing resulting in aggregate gross proceeds to the Company of at least $2.0 million (including amounts received in connection with the conversion of the notes) and will be issued together with a five-year warrant to purchase additional shares of such preferred stock. An initial closing of the sale of notes and warrants was held on the Effective Date of the Note and Warrant Purchase Agreement and involved the sale to Avalon Ventures of a note (and a corresponding warrant) representing an initial principal amount of $1.0 million.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any security. The securities issued pursuant to the Note and Warrant Purchase Agreement have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws and may not be offered or sold in the United States absent registration under the Securities Act of 1933, as amended, and applicable state securities laws or an applicable exemption from registration requirements.
**DD**
Akesis Pharmaceuticals has a pipeline of innovative oral product candidates for the treatment of diabetes and related metabolic disorders. These product candidates are supported by issued and filed U.S. patents for both prescription and over-the-counter treatments that combine anti-diabetic trace minerals with certain classes of diabetes oral agents. Akesis' product candidates have demonstrated preliminary evidence of efficacy in lowering and controlling blood glucose levels in patients with Type 2 diabetes. Blood sugar control via oral drugs represents a market opportunity in the billions of dollars, as reports indicate that approximately 20 million people suffer from diabetes in the United States alone. More information can be found at www.akesis.com.
CONACT INFORMATION:
Akesis Pharmaceuticals, Inc.
888 Prospect Street
Suite 320
La Jolla , CA 92037
Phone: (858) 454-4311
I know you guys were dopers! LMBSO!
market doesn't know which way to go. i like the upticks.
Heading north again Mick..AKES Bid: 0.55 Ask: 0.67 Last: 0.67 ($): 0.01 Vol: 7,878 |
yes, fda is the key here.
If they can just get one of those past the FDA mick..WOW!!$$
small down ticks this morning.
Detailed Quote for Akesis Pharmaceuticals Inc. (AKES)
$ 0.60 -0.06 (-9.09%) Volume: 7.0 k 10:34 AM EST Nov 6, 2007
$ 0.66 0.11 (+20.00%) Volume: 3.5 k 3:53 PM EST Nov 5, 2007
Detailed Quote for Akesis Pharmaceuticals Inc. (AKES)
$ 0.55 -0.13 (-19.12%) Volume: 966 9:30 AM EDT Nov 2, 2007
hi leon, good afternoon. this could be a good one.
o/s aren't bad either.
Followers
|
1
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
22
|
Created
|
11/03/07
|
Type
|
Free
|
Moderators |
About Akesis:
Akesis Pharmaceuticals has a pipeline of innovative oral product candidates for the treatment of diabetes and related metabolic disorders. These product candidates are supported by issued and filed U.S. patents for both prescription and over-the-counter treatments that combine anti-diabetic trace minerals with certain classes of diabetes oral agents. Akesis’ product candidates have demonstrated preliminary evidence of efficacy in lowering and controlling blood glucose levels in patients with Type 2 diabetes. Blood sugar control via oral drugs represents a market opportunity in the billions of dollars, as reports indicate that approximately 20 million people suffer from diabetes in the United States alone. More information can be found at http://www.akesis.com/
Jay Lichter, Ph.D., President & CEO
858-454-4311
jlichter@akesis.com
Corporate Offices:
11408 Sorrento Valley Road
San Diego, CA 92121
Phone: 858.454.4311
Fax: 858.348.2183
Mailing Address:
888 Prospect Street, Suite 320
La Jolla, CA 92037
info@akesis.com
Corporate Counsel:
Paul, Hastings, Janofsky and Walker, LLC
3579 Valley Centre Drive
San Diego, CA 92130
United States of America
Tel: 1.858.720.2500
Fax: 1.858.720.2555
Attention: Carl Sanchez, Esq.
IR/PR Inquiries
Don Markley
Vice President
Lippert/Heilshorn & Associates, Inc.
dmarkley@lhai.com
http://www.lhai.com/
Investor Relations for Growing Companies
2049 Century Park East, Suite 2710
Los Angeles, CA 90067
Phone: 310.691.7100
Fax: 310.691.7150
Authorized Shares: 50,000,000
Outstanding Shares: 22,580,000
Approx. Float: 8,650,000
Insiders Hold: 61.68%
Institutions Hold: 9.0%
Kinsella Kevin J 8,131,775
Steel (John F IV) 2.3M
Segall, Bryant 2.0M
Keeling (Gary R) 1.8M
Hendrick (John T) 46.8K
Avalon Ventures VII L P 5,297,500
8/13/2007 10-QSB http://yahoo.brand.edgar-online.com/fetchFilingFrameset.aspx?dcn=0001193125-07-180724&Type=HTML
Past Press Releases: http://finance.yahoo.com/q/h?s=AKES.OB
http://quotes.barchart.com/texadv.asp?sym=akes
DISCLAIMER:
Opinions expressed on this board are just that. Opinions. We are not a licensed brokers. Trading strategies discussed on this board are often high risk and not suitable everyone. If you are losing money in the market, you may wish to seek the advice of a licensed securities professional.
No one is responsible for your gains or losses in the market except you. If you follow stocks, strategies discussed on this board, you may lose all your money. Please weigh the strategies discussed here carefully against what you are willing to risk.
Please do your own due diligence before buying or selling any security in the open market, there are no guarantees.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |